Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Personalis Inc (PSNL)

Personalis Inc (PSNL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 375,446
  • Shares Outstanding, K 31,710
  • Annual Sales, $ 65,210 K
  • Annual Income, $ -25,080 K
  • 60-Month Beta N/A
  • Price/Sales 5.76
  • Price/Cash Flow N/A
  • Price/Book 3.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.33
  • Low Estimate -0.34
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +61.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.69 +29.93%
on 05/08/20
13.25 -4.98%
on 05/26/20
+2.65 (+26.66%)
since 05/01/20
3-Month
4.27 +194.85%
on 03/17/20
13.25 -4.98%
on 05/26/20
+3.86 (+44.22%)
since 02/28/20

Most Recent Stories

More News
Personalis: 1Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Personalis Inc. (PSNL) on Thursday reported a loss of $9.1 million in its first quarter.

PSNL : 12.66 (+6.93%)
Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in three upcoming virtual investor conferences.

MHMNF : 54.5000 (unch)
PSNL : 12.66 (+6.93%)
Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma Research Solutions, the latest expansion of the company's portfolio of comprehensive...

PSNL : 12.66 (+6.93%)
Personalis: 4Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Personalis Inc. (PSNL) on Wednesday reported a loss of $6.6 million in its fourth quarter.

PSNL : 12.66 (+6.93%)
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced...

ADXS : 0.7045 (+2.10%)
PSNL : 12.66 (+6.93%)
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced...

ADXS : 0.7045 (+2.10%)
PSNL : 12.66 (+6.93%)
Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel...

MKKGY : 23.3700 (-0.93%)
PSNL : 12.66 (+6.93%)
Personalis: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Personalis Inc. (PSNL) on Wednesday reported a loss of $6.9 million in its third quarter.

PSNL : 12.66 (+6.93%)
Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...

PSNL : 12.66 (+6.93%)
Personalis Appoints Karin Eastham to Its Board of Directors

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more...

ILMN : 366.50 (+0.95%)
MOR : 32.34 (-0.09%)
VCYT : 25.54 (+2.41%)
PSNL : 12.66 (+6.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade PSNL with:

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

2nd Resistance Point 12.63
1st Resistance Point 12.24
Last Price 12.65
1st Support Level 11.34
2nd Support Level 10.83

See More

52-Week High 31.88
Fibonacci 61.8% 21.33
Fibonacci 50% 18.07
Fibonacci 38.2% 14.82
Last Price 12.65
52-Week Low 4.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar